Survival and tumor characteristics of German hereditary breast cancer patients
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Reports from different countries have been inconclusive in attempting to relate the BRCA1 mutation status to the survival of breast cancer patients. The purpose of this study was to investigate overall and disease-free survival for German hereditary breast cancer patients. Data on clinical outcome and data on age at diagnosis of breast cancer, histology, tumor size, lymph node status, histological grade, and laterality of 36 breast cancer patients from 12 families with a BRCA1 mutation and from one family with strong evidence for linkage to BRCA1 were compared with those of 49 hereditary breast cancer patients from 23 families that did not harbor a BRCA1 mutation. Overall and disease-free survival was estimated for both groups. BRCA1 mutation carriers had a significantly earlier age of diagnosis than non-carriers (p = 0.0001) and more frequently developed contralateral breast cancer (p = 0.04). Also, BRCA1-associated tumors more frequently were of larger size (p = 0.041) and higher grade of malignancy (p = 0.005) than non-BRCA1-associated tumors. Whereas no difference in overall survival was seen, disease-free survival at 10 years differed significantly with 53.3% for BRCA1 mutation carriers and 76% for non-carriers (p = 0.02). However, after stratification for age and in multivariate analysis for mutation status, age, and bilaterality, it was shown that the worse prognosis for BRCA1 mutation carriers disappeared. Our results suggest that the worse prognosis of BRCA1 mutation…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297 · cited 1×
“For statistical analysis, mutation carriers were compared to non-carriers using univariate survival analysis using the Kaplan-Meier estimator and multivariate survival analysis using the proportional hazard model [ 27 ].”
MethodA Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071 · cited 1×
“In the context of high-risk families, one important gene is the BRCA1 gene on chromosome 17q21 [ 3 ].”
BackgroundGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationLinkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550 · cited 1×
“Our study also supported the reported earlier age of diagnosis of women harboring a BRCA1 mutation [ 7 , 9]. Breast cancers in younger patients generally have adverse prognostic factors [29, 30] and were found to have a worse prognosis, especially in patients under 40 years of age [31, 32].”
ResultRisks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Unusual case of Smith‐Lemli‐Opitz syndrome “type II”
Seller, M. J., Russell, J., & Tint, G. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560305 · Cited by 585
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
Marcus, J. N., Watson, P., Page, D. L., Narod, S. A., Lenoir, G. M., Tonin, P., Linder-Stephenson, L., Salerno, G., Conway, T. A., & Lynch, H. T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w · Cited by 454 · cited 2×
“Two studies reported a significantly worse prognosis for BRCA1mutation carriers [19, 20], another reported better survival [18], and five other studies showed no differences [ 12 , 16, 17, 21, 22].”
BackgroundResultSurvival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452 · cited 3×
“This frequency of early contralateral breast cancers is similar to the frequency that has been reported by Verhoog et al. [ 17 ] who showed development of contralateral breast cancer in 25% of women with a BRCA1 mutation within the same time period.”
ResultInfluentialTumour biological features of BRCA1-induced breast and ovarian cancer
Jóhannsson, Ó. T., Idvall, I., Anderson, C., Borg, Å., Barkardóttir, R. B., Egilsson, V., & Olsson, H. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 345
Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., & Bergh, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.462 · Cited by 327
BRCA-associated breast cancer in young women.
Robson, M., Gilewski, T., Haas, B., Levin, D., Borgen, P., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., Lesser, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 302
Breast cancer outcome and predictors of outcome: are there age differentials?
Albain, K. S., Allred, D. C., & Clark, G. M. (1994) · PubMed · Cited by 264
Why are local recurrences after breast-conserving therapy more frequent in younger patients?
Kurtz, J. M., Jacquemier, J., Amalric, R., Brandone, H., Ayme, Y., Hans, D., Bressac, C., & Spitalier, J. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.4.591 · Cited by 258
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254
The influence of young age on outcome in early stage breast cancer
Fowble, B. L., Schultz, D. J., Overmoyer, B., Solin, L. J., Fox, K., Jardines, L., Orel, S., & Glick, J. H. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90515-0 · Cited by 241
Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Eisinger, F., Stoppa‐Lyonnet, D., Longy, M., Kerangueven, F., Noguchi, T., Bailly, C., Vincent‐Salomon, A., Jacquemier, J. D., Birnbaum, D., & Sobol, H. (1996) · PubMed · Cited by 188
Porter, D. E., Cohen, B. B., Wallace, M. R., Smyth, E., Chetty, U., Dixon, J. M., Steel, C. M., & Carter, D. C. (1994) · Journal of British Surgery · doi:10.1002/bjs.1800811038 · Cited by 122 · cited 2×
“Two studies reported a significantly worse prognosis for BRCA1mutation carriers [19, 20], another reported better survival [ 18 ], and five other studies showed no differences [12, 16, 17, 21, 22].”
BackgroundResultFoulkes, W. D., Wong, N., Brunet, J., Bégin, L. R., Zhang, J. C., Martinez, J. J., Rozen, F., Tonin, P. N., Narod, S. A., Karp, S. E., et al. (1997) · PubMed · Cited by 122
Survival After Breast Cancer in Ashkenazi Jewish BRCA1 and BRCA2 Mutation Carriers
Lee, J. S., Wacholder, S., Struewing, J. P., McAdams, M., Pee, D., Brody, L. C., Tucker, M. A., & Hartge, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.259 · Cited by 100 · cited 2×
“No survival differences among BRCA1 and BRCA2 mutation carriers and non-carriers were found in two studies of Ashkenazi Jewish women [16, 22 ], and no survival differences were found among BRCA1 mutation carriers from Holland and southern Sweden when compared to sporadic patients from cancer registries in those countr…”
ResultRosen, P. P., LESSER, M. L., & Kinne, D. W. (1985) · Journal of Surgical Oncology · doi:10.1002/jso.2930280204 · Cited by 99 · cited 1×
“Our study also supported the reported earlier age of diagnosis of women harboring a BRCA1 mutation [7, 9]. Breast cancers in younger patients generally have adverse prognostic factors [ 29 , 30] and were found to have a worse prognosis, especially in patients under 40 years of age [31, 32].”
ResultThe BRCA1 and BRCA2 breast cancer genes
Casey, G. (1997) · Current Opinion in Oncology · doi:10.1097/00001622-199701000-00014 · Cited by 93 · cited 1×
“About one in eight to ten women will develop breast cancer during her lifetime [ 1 ].”
BackgroundPathology and heredity of breast cancer in younger women.
Marcus, J. N., Watson, P. A., Page, D. L., & Lynch, H. T. (1994) · PubMed · Cited by 81
Survival in early-onset BRCA1 breast-cancer patients
Ansquer, Y., Gautier, C., Fourquet, A., Asselain, B. J. R., & Stoppa‐Lyonnet, D. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79248-5 · Cited by 80 · cited 1×
“Ansquer et al. reported worse overall survival for early-onset BRCA1 mutation carriers compared with early-onset non-carriers in France [ 37 ].”
ResultSobol, H., Stoppa‐Lyonnet, D., Paillerets, B. B., Peyrat, J. P., Kerangueven, F., Janin, N., Noguchi, T., Eisinger, F., Guinebretière, J. M., Jacquemier, J. D., et al. (1996) · PubMed · Cited by 64
Histoprognostic grade in BRCA1-associated breast cancer
Jacquemier, J. D., Eisinger, F., Birnbaum, D., & Sobol, H. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91060-3 · Cited by 63
BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
Shen, D., & Vadgama, J. V. (1999) · PubMed · Cited by 36
Chang-Claude, J., Becher, H., Eby, N., Bastert, G., Wahrendorf, J., & Hamann, U. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01208638 · Cited by 32
Self-citationAge at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer
Cornells, R. S., Vasen, H. F. A., Meijers-Heijboer, H. E. J., Ford, D., van Vliet, M., van Tilborg, A. A. G., Cleton, F. J., Klijn, J. G. M., Menko, F. H., Khan, P. M., et al. (1995) · Human Genetics · doi:10.1007/bf00223866 · Cited by 24 · cited 1×
“Our study also supported the reported earlier age of diagnosis of women harboring a BRCA1 mutation [7, 9 ]. Breast cancers in younger patients generally have adverse prognostic factors [29, 30] and were found to have a worse prognosis, especially in patients under 40 years of age [31, 32].”
ResultHamann, U., Brauch, H. B., Garvin, A. M., Bastert, G., & Scott, R. J. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199702)18:2<126::aid-gcc7>3.0.co;2-4 · Cited by 24 · cited 2×
“Genetic analysis of German breast and/or ovarian cancer families have resulted in the identification of 13 families with BRCA1 germline mutations [ 23 , 24].”
BackgroundSelf-citationAge as a prognostic factor in breast cancer.
Vanlemmens, L., Hebbar, M., Peyrat, J. P., & Bonneterre, J. M. (1998) · PubMed · Cited by 23
Hamann, U., Brauch, H. B., Garvin, A. M., Bastert, G., & Scott, R. J. (1997) · Genes Chromosomes and Cancer · Cited by 23
Self-citationBRCA1 mutations and survival in women with ovarian cancer.
Brunet, J., Narod, S. A., Tonin, P. N., & Foulkes, W. D. (1997) · PubMed · Cited by 20
Long-term outcome in women less than 30 years of age with breast cancer
Feldman, A. L., & Welch, J. P. (1998) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199807)68:3<179::aid-jso9>3.0.co;2-2 · Cited by 18
Long-term outcome in women less than 30 years of age with breast cancer
Feldman, A. L., & Welch, J. P. (1998) · Journal of Surgical Oncology · Cited by 18
Survival of patients with breast cancer and BRCA1 mutations
Foulkes, W. D., Wong, N., Rozen, F., Brunet, J., & Narod, S. A. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79091-7 · Cited by 16 · cited 2×
“These findings are in contrast to two reports of Foulkes et al. that showed worse survival for Ashkenazi BRCA1 mutation carriers than for non-carriers [19, 20 ].”
ResultLow frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families.
Hamann, U., Häner, M., Stosiek, U., Bastert, G., & Scott, R. J. (1997) · Journal of Medical Genetics · doi:10.1136/jmg.34.11.884 · Cited by 15 · cited 2×
“Twelve families had an identified BRCA1 germline mutation, one family had strong evidence for linkage to BRCA1[26], and 23 families were negative for a BRCA1 mutation [23, 24 ].”
BackgroundSelf-citationGerman family study on hereditary breast-ovarian cancer.
Hamann, U., Becher, H., Zimmermann, T., Pella, K., Bastert, G., & Chang-Claude, J. C. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.8.633 · Cited by 9
Self-citation
Research works printed but not linked: 1
- Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. Häufigkeiten und Trends. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (Hrsg), Saarbücken, 1997
Cited by
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
“Several reports suggested that women with germline mutations in BRCA1 are more likely to die from their disease than are women with sporadic breast cancer [3–6].”
BackgroundThe Genetic Epidemiology of Breast Cancer Genes
Thompson, D., & Easton, D. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048770.90334.3b · Cited by 257
Zhong, Q., Peng, H.-L., Zhao, X., Zhang, L., & Hwang, W.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1816 · Cited by 203
“Second, because of the variety of endpoints reported in breast cancer studies, we operationally defined breast cancer PFS to include MFS or DDFS for studies that did not provide DFS and had to exclude LRFS and CRFS results (which were considered to be parts of PFS for some studies) from a few studies.”
Influential
Metadata
- Authors
- Hamann, U., & Sinn, H.-P.
- Affiliations
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Venue
- Breast Cancer Research and Treatment
- Published
- 2000-01
- Volume
- 59
- Issue
- 2
- Pages
- 185-192
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2078493457
- Semantic Scholar
- 5dafca3b3ff9d49bd3a1d2cfb00d36ecd01349a6
- Cited by
- 48
- References
- 42
- Citations by year
- 2022: 1 · 2020: 1 · 2019: 1 · 2016: 3 · 2015: 2 · 2014: 2 · 2012: 1
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- hereditary breast cancer, BRCA1 mutation, disease-free survival, overall survival, age at diagnosis, contralateral breast cancer, tumor size, histological grade, prognostic factors, German patients
- MeSH terms
- Adult, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Survival Analysis, Point Mutation, Age of Onset, Genes, BRCA1, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.